Aprutumab, {a distinctive therapeutic, offers {a important step forward in treating cancers fueled by FGFR2 fusions. This targeted agent operates by specifically inhibiting FGFR2, a protein often overexpressed in https://henriktnl424126.wikiexpression.com/user